Familial adult onset hyperinsulinism due to an activating glucokinase mutation: Implications for pharmacological glucokinase activation

Clinical Endocrinology

Volumn 81, Issue 6, 2014, Pages 855-861

  Challis, Benjamin G ^a   Harris, Julie ^a   Sleigh, Alison ^b   Isaac, Iona ^a   Orme, Steve M ^c   Seevaratnam, Nandini ^d   Dhatariya, Ketan ^e   Simpson, Helen L ^a   Semple, Robert K ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; C PEPTIDE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; FEMALE; GENE MUTATION; GENE SEQUENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINISM; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPOGENESIS; MIDDLE AGED; ORAL GLUCOSE TOLERANCE TEST; AGED; DNA SEQUENCE; FAMILY; GENETICS; HETEROZYGOTE; MALE; MUTATION; PEDIGREE;

ADULT; AGED; FAMILY; FEMALE; GLUCOKINASE; HETEROZYGOTE; HUMANS; HYPERINSULINISM; MALE; MIDDLE AGED; MUTATION; PEDIGREE; SEQUENCE ANALYSIS, DNA;

EID: 84912570789     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12517     Document Type: Article

References (25)

1. Matschinsky, F.M., (2013) GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends in Pharmacological Sciences, 34, 90-99.
2. Glaser, B., Kesavan, P., Heyman, M., et al,. (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. The New England Journal of Medicine, 338, 226-230.
3. Wabitsch, M., Lahr, G., Van de Bunt, M., et al,. (2007) Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabetic Medicine, 24, 1393-1399.
4. Beer, N.L., van de Bunt, M., Colclough, K., et al,. (2011) Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans. The Journal of Biological Chemistry, 286, 19118-19126.
5. Christesen, H.B., Jacobsen, B.B., Odili, S., et al,. (2002) The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes, 51, 1240-1246.
6. O'Doherty, R.M., Lehman, D.L., Telemaque-Potts, S., et al,. (1999) Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes, 48, 2022-2027.
7. Ferre, T., Riu, E., Franckhauser, S., et al,. (2003) Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia, 46, 1662-1668.
8. De Ceuninck, F., Kargar, C., Ilic, C., et al,. (2013) Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. British Journal of Pharmacology, 168, 339-353.
9. Peter, A., Stefan, N., Cegan, A., et al,. (2011) Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. The Journal of Clinical Endocrinology and Metabolism, 96, E1126-E1130.
10. Orho-Melander, M., Melander, O., Guiducci, C., et al,. (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes, 57, 3112-3121.
11. Beer, N.L., Tribble, N.D., McCulloch, L.J., et al,. (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Human Molecular Genetics, 18, 4081-4088.
12. Meininger, G.E., Scott, R., Alba, M., et al,. (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care, 34, 2560-2566.
13. Szczepaniak, L.S., Nurenberg, P., Leonard, D., et al,. (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology Endocrinology and Metabolism, 288, E462-E468.
14. Greenfield, J.R., Farooqi, I.S., Keogh, J.M., et al,. (2009) Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. The American Journal of Clinical Nutrition, 89, 106-113.
15. Murphy, R., Tura, A., Clark, P.M., et al,. (2009) Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor. Diabetologia, 52, 154-159.
16. Christesen, H.B., Brusgaard K., Beck Nielsen H., et al,. (2008) Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacks. Clinical Endocrinology, 68, 747-755.
17. Cryer, P.E., Axelrod, L., Grossman, A.B., et al,. (2009) Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 94, 709-728.
18. Semple, R.K., Savage, D.B., Cochran, E.K., et al,. (2011) Genetic syndromes of severe insulin resistance. Endocrine Reviews, 32, 498-514.
19. Cuesta-Munoz, A.L., Huopio, H., Otonkoski, T., et al,. (2004) Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes, 53, 2164-2168.
20. Tornovsky-Babeay, S., Dadon D., Ziv O., et al,. (2014) Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metabolism, 19, 109-121.
21. Kassem, S., Bhandari, S., Rodriguez-Bada, P., et al,. (2010) Large islets, beta-cell proliferation, and a glucokinase mutation. The New England Journal of Medicine, 362, 1348-1350.
22. Agius, L., (2008) Glucokinase and molecular aspects of liver glycogen metabolism. The Biochemical Journal, 414, 1-18.
23. Naressi, A., Couturier, C., Devos, J.M., et al,. (2001) Java-based graphical user interface for the MRUI quantitation package. MAGMA, 12, 141-152.
24. Vanhamme, L., van den Boogaart, A., &, Van Huffel, S., (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. Journal of Magnetic Resonance, 129, 35-43.
25. Semple, R.K., Sleigh, A., Murgatroyd, P.R., et al,. (2009) Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. The Journal of Clinical Investigation, 119, 315-322.